CFH and B-cell chronic lymphocytic leukemia: In combination with ofatumumab or RTX, human recombinant Factor H-derived short-consensus repeat 18–20 (hSCR18–20) increased susceptibility of primary CLL cells to CDC by abrogating Factor H function on the surface of CLL cells (106, 107).